Latest Information Update: 04 Oct 2004
At a glance
- Originator Ajinomoto
- Mechanism of Action Factor Xa inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 30 Sep 2004 Discontinued - Preclinical for Thrombosis in Japan (unspecified route)
- 07 Jan 2004 No development reported - Preclinical for Thrombosis in Japan (unspecified route)
- 09 Jun 2000 New profile